Long intergenic non-protein coding RNA 2454 (LINC02454)

Long intergenic non-protein coding RNA 2454 (LINC02454) is a long non-coding RNA (lncRNA) highly expressed in several malignancies, including papillary thyroid carcinoma, glioma, head and neck, and laryngeal squamous cell carcinoma[1][2][4][5][6]. It promotes tumor cell proliferation, migration, invasion, and inhibits apoptosis, acting as an oncogene. Mechanistically, LINC02454 regulates cancer progression through modulating chromatin interactions, cis-activating oncogenes (notably HMGA2 via CREB1), and affecting pathways such as ECM-receptor interaction and MAPK signaling. In glioma, LINC02454 influences sensitivity to temozolomide by modulating chromatin loops that regulate SORBS2 and DDR1 expression[2]. LINC02454 overexpression is associated with larger tumor size, advanced clinical stage, lymph node metastasis, and poorer patient prognosis, making it a putative diagnostic and prognostic biomarker[4][5][6]. Its role as a therapeutic target is under investigation, with emerging evidence supporting its functional importance in tumor biology[1][2][4].

Other names

LINC02454

Modulates chromatin interactions to regulate gene expression (e.g., SORBS2, DDR1, HMGA2); Regulates phosphorylation/nuclear translocation of CREB1 and transcriptional activation of HMGA2.